Myungmoon Pharm Co Ltd
KRX:017180
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| KR |
M
|
Myungmoon Pharm Co Ltd
KRX:017180
|
59.7B KRW |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
913.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
570.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
270.7B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.3B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
234.6B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.4B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.9B USD |
Loading...
|
Market Distribution
| Min | -646.5% |
| 30th Percentile | 12.8% |
| Median | 19.7% |
| 70th Percentile | 32.2% |
| Max | 54 001.3% |
Other Profitability Ratios
Myungmoon Pharm Co Ltd
Glance View
MYUNGMOON Pharm Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2008-07-10. Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceuticals. Its products include ethical (ETC) drugs and over the counter (OTC) drugs. Its ETC drugs include anesthetic agents, digestive system drugs, rheumatoid arthritis remedies, central nervous system drugs, circulatory drugs, anti-depressant agents, anti-diabetic agents, antibiotics, hormone agents, narcotics and drugs for dermatology systems. Its OTC drugs include antinauseant agents, hepatic agents, immunologic agents, antidiarrheal agents, skin external preparations, antiallergic agents, muscle relaxants, cold drugs and parasiticides. The firm is also involved in the operation golf courses. January 2, 2012, the Company completed the merger with its wholly owned subsidiary.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Myungmoon Pharm Co Ltd is 54.8%, which is below its 3-year median of 55.3%.
Over the last 3 years, Myungmoon Pharm Co Ltd’s Gross Margin has increased from 46.9% to 54.8%. During this period, it reached a low of 46.9% on Aug 30, 2022 and a high of 56.3% on Dec 31, 2024.
